News

Echinacoside (ECH), a naturally occurring compound derived from certain plants, particularly echinacea, was shown to ease the signs and symptoms of pulmonary arterial hypertension (PAH) in rats in a laboratory study. The researchers found that ECH worked by normalizing calcium signaling in the muscle cells lining blood vessels, which…

An expert panel convened by the American Lung Association and the Pulmonary Hypertension Association has developed practical flowcharts to help U.S. healthcare providers diagnose and treat pulmonary hypertension (PH). The meeting aimed to guide providers through the most recent European guidelines for PH diagnosis and treatment. The…

A part of NOTCH3, a protein involved in disease-related alterations in blood vessels, may be a biomarker of idiopathic pulmonary arterial hypertension (iPAH), a rare type of pulmonary hypertension (PH) that’s hard to diagnose, a recent study suggests. The researchers found that blood levels of the extracellular, or outside-the-cell,…

In people with pulmonary arterial hypertension (PAH), adding Winrevair (sotatercept-csrk) to standard therapy was linked to longer survival, fewer safety events, and a lower need for lung transplant compared with standard therapy alone, according to new real-world data. “These findings extend clinical trial evidence, suggesting sotatercept [Winrevair] offers meaningful…

Levels of the enzyme PRDX2 increase as a protective response in chronic thromboembolic pulmonary hypertension (CTEPH) and help reduce damage to blood vessels in the lungs, a new study in laboratory rats has found. The researchers discovered that the antioxidant enzyme worked to reduce vessel damage by limiting inflammation,…

A weight-based dose regimen of Uptravi (selexipag) for children with pulmonary arterial hypertension (PAH) achieves drug exposure similar to that of the standard adult dose regimen, according to results from a Phase 2 clinical trial. The study also found that the weight-based Uptravi regimen for kids is comparable…

Yutrepia, an inhaled dry powder formulation of treprostinil that won regulatory approval in the U.S. in May 2025, was prescribed to more than 2,800 patients through December of last year, according to its developer Liquidia. Overall, more than 2,200 patients have started treatment, per the biopharmaceutical company, which…

Women with pulmonary hypertension have a lower risk of death than men, a difference that persists regardless of how severe the disease is, how old patients are, or how they are treated, a large study found. The disparity mainly affected white patients, the researchers said. “These insights provide new…

People with chronic thromboembolic pulmonary hypertension (CTEPH) continue to experience significant symptoms that interfere with daily life, even when receiving treatment, according to a real-world U.S. study. The study also found that people treated at Pulmonary Hypertension Association (PHA)-accredited centers tended to have more severe…

Early diagnosis of pulmonary arterial hypertension (PAH), less than six months after symptom onset, improves five-year survival by 42% compared with delayed diagnosis of about two years or more, a recent study shows. The study also found that high blood pressure during heart contraction or normal pressure during heart relaxation,…

Routine heart ultrasound measurements of left ventricular (LV) underfilling may significantly improve the prediction of poorer outcomes in people with pulmonary arterial hypertension (PAH) beyond currently used prognostic tools, a study has found. LV underfilling refers to the extent to which the left ventricle, the heart chamber that pumps…

Pulmonary hypertension (PH) in extremely premature infants — those born before 28 weeks of pregnancy — who also have bronchopulmonary dysplasia (BPD) usually resolves within the first year and does not…